SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SynAct Pharma expects Part 1 results in 2026, pending regulatory feedback

Valid market news retained in the public archive without immediate LiveCast distribution.

AB

Related stories